Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Losmapimod - Fulcrum Therapeutics

Drug Profile

Losmapimod - Fulcrum Therapeutics

Alternative Names: 856553; FTX-1821; GS856553; GSK 856553; GW 856553; GW856553X

Latest Information Update: 20 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Fulcrum Therapeutics; GlaxoSmithKline; GSK
  • Class Amides; Analgesics; Anti-inflammatories; Antidepressants; Antihyperlipidaemics; Antirheumatics; Antivirals; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Pyridines; Small molecules; Vascular disorder therapies
  • Mechanism of Action DUX4 protein inhibitors; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Facioscapulohumeral muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute coronary syndromes; COVID 2019 infections; Facioscapulohumeral muscular dystrophy
  • Phase II Chronic obstructive pulmonary disease; Focal segmental glomerulosclerosis
  • No development reported Inflammation
  • Discontinued Atherosclerosis; Dyslipidaemias; Major depressive disorder; Neuropathic pain; Rheumatoid arthritis

Most Recent Events

  • 14 May 2024 Fulcrum Therapeutics announces intention to submit NDA to US FDA for Facioscapulohumeral muscular dystrophy in the US
  • 13 May 2024 Losmapimod licensed to Sanofi ex USA territories for the treatment of Facioscapulohumeral muscular dystrophy
  • 13 May 2024 Fulcrum Therapeutics announces intention to submit regulatory application in Japan for Facioscapulohumeral muscular dystrophy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top